|
🐜
|
Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors.
44 auth.
B. Lanman,
Jennifer R. Allen,
J. Allen,
A. Amegadzie,
K. Ashton,
S. Booker,
J. Chen,
N. Chen,
M. Frohn,
G. Goodman,
D. J. Kopecky,
Longbin Liu,
Patricia Lopez,
J. D. Low,
V. Ma,
...
A. Minatti,
Thomas T. Nguyen,
N. Nishimura,
Alexander J. Pickrell,
Anthony B. Reed,
Y. Shin,
Aaron C. Siegmund,
N. Tamayo,
C. Tegley,
Mary C. Walton,
Hui-Ling Wang,
Ryan P. Wurz,
May Xue,
Kevin C Yang,
Pragathi Achanta,
M. Bartberger,
J. Canon,
L. Hollis,
J. McCarter,
C. Mohr,
K. Rex,
A. Y. Saiki,
Tisha San Miguel,
Laurie P. Volak,
Kevin H. Wang,
D. Whittington,
S. Zech,
J. Lipford,
V. Cee
|
8 |
2019 |
8
🐜
|
|
🐜
|
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.
53 auth.
Jin-Shyr Chen,
C. Hsu,
N. Chiang,
N. Chiang,
N. Chiang,
Cheng-chung Tsai,
Hsiao-Hui Tsou,
Shi Huang,
L. Bai,
I. Chang,
H. Shiah,
C. Ho,
C. Yen,
Kuan-Der Lee,
C-F. Chiu,
...
K. Rau,
M. S. Yu,
Y. Yang,
R. Hsieh,
Jang-Yang Chang,
Jang-Yang Chang,
Y. Shan,
Y. Chao,
L.-T. Chen,
L.-T. Chen,
L.-T. Chen,
Wen-Chi Shen,
H. Hsu,
Chih-Hung Hsu,
Ying-Chun Shen,
Tsang-En Wang,
Chung-Pin Li,
Ming-Huang Chen,
W. Kao,
P. Chang,
Cheng‐Chung Wu,
Chien-Lin Teng,
Chang-Hsien Lu,
Shyh‐Jer Lin,
Being‐Whey Wang,
Yen-Yang Chen,
Y. Chin,
Tsai-Rong Chung,
Wei-Lan Yu,
Mei-Hua Lee,
Ling-Fang Lin,
Pei-Chyi Lin,
Ya-Ling Wu,
Hui-Ling Wang,
Lina Lu,
Shiang-Yi Chen,
Chih-Chu Wu,
Tengfei Wei
|
7 |
2015 |
7
🐜
|
|
🦁
|
Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.
17 auth.
Hui-Ling Wang,
J. Katon,
C. Balan,
A. Bannon,
C. Bernard,
E. Doherty,
C. Dominguez,
N. Gavva,
V. Gore,
V. Ma,
...
N. Nishimura,
S. Surapaneni,
P. Tang,
R. Tamir,
O. Thiel,
J. Treanor,
M. H. Norman
|
5 |
2007 |
5
🦁
|
|
🦁
|
Synthesis, Characterization and the Antioxidative Activity of Copper(II), Zinc(II) and Nickel(II) Complexes with Naringenin
Hui-Ling Wang,
Zheng-yin Yang,
Bao‐dui Wang
|
5 |
2006 |
5
🦁
|
|
🐜
|
Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
22 auth.
L. Schenkel,
Xin Huang,
A. Cheng,
H. L. Deak,
E. Doherty,
R. Emkey,
Yan Gu,
H. Gunaydin,
Joseph L. Kim,
J. Lee,
...
R. Loberg,
P. Olivieri,
J. Pistillo,
Jin Tang,
Q. Wan,
Hui-Ling Wang,
Shen-wu Wang,
Mary C Wells,
Bin Wu,
Violeta L Yu,
Liqin Liu,
Stephanie D. Geuns-Meyer
|
5 |
2011 |
5
🐜
|
|
🐜
|
Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors.
13 auth.
R. Rzasa,
Matthew R. Kaller,
Gang Liu,
E. Magal,
Thomas T. Nguyen,
T. Osslund,
D. Powers,
V. Santora,
V. Viswanadhan,
Hui-Ling Wang,
...
Xiao-Yi Xiong,
W. Zhong,
M. H. Norman
|
5 |
2007 |
5
🐜
|
|
🐜
|
Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors.
16 auth.
Bin Wu,
Hui-Ling Wang,
V. Cee,
B. Lanman,
Thomas E. Nixey,
L. Pettus,
Anthony B. Reed,
Ryan P Wurz,
Nadia Guerrero,
Christine Sastri,
...
J. Winston,
J. Lipford,
Matthew R. Lee,
C. Mohr,
K. Andrews,
A. Tasker
|
4 |
2015 |
4
🐜
|
|
🐢
|
Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
33 auth.
L. Pettus,
K. Andrews,
S. Booker,
Jie Chen,
V. Cee,
F. Chavez,
Yuping Chen,
Heather Eastwood,
Nadia Guerrero,
B. Herberich,
D. Hickman,
B. Lanman,
Jimmy Laszlo,
Matthew R. Lee,
J. Lipford,
...
Bethany Mattson,
C. Mohr,
Y. Nguyen,
M. H. Norman,
D. Powers,
Anthony B. Reed,
K. Rex,
Christine Sastri,
N. Tamayo,
Paul Wang,
J. Winston,
Bin Wu,
Tian Wu,
Ryan P. Wurz,
Yang Xu,
Yihong Zhou,
A. Tasker,
Hui-Ling Wang
|
4 |
2016 |
4
🐢
|
|
🦁
|
The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.
17 auth.
Hui-Ling Wang,
V. Cee,
F. Chavez,
B. Lanman,
Anthony B. Reed,
Bin Wu,
Nadia Guerrero,
J. Lipford,
Christine Sastri,
J. Winston,
...
K. Andrews,
Xin Huang,
Matthew R. Lee,
C. Mohr,
Yang Xu,
Yihong Zhou,
A. Tasker
|
4 |
2015 |
4
🦁
|
